Mirtazapine Torrent Pharma (Uk) (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes serotonin 5‑HT2 and 5‑HT3 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission, leading to mood elevation and reduced anxiety.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often causes more sedation and weight gain but may be advantageous for patients with insomnia or poor appetite. Its distinct receptor profile can be useful when SSRIs are ineffective or poorly tolerated.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Mirtazapine Torrent Pharma is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis, severe neutropenia, hepatotoxicity, seizures, hyponatremia, and the emergence of suicidal thoughts or behaviors, particularly during the early weeks of therapy or when doses are changed.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) within 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment. Caution is advised for patients with a history of bipolar disorder, seizure disorders, or uncontrolled hypertension.